Investigating a specific protein's role in ovarian cancer progression
The role of tumor endothelium-specific prion-gene PRND in epithelial ovarian cancer
This study is looking at a protein called Doppel that appears in ovarian cancer to see if it can help us find the cancer earlier and create better treatments, which could be really helpful for patients dealing with this condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-11044391 on NIH RePORTER |
What this research studies
This research focuses on understanding how a protein called Doppel, which is found in tumors, contributes to the progression of epithelial ovarian cancer (EOC). The study aims to evaluate whether Doppel can serve as a specific biomarker for early detection of EOC and to explore new treatment strategies that target this protein. By examining the relationship between Doppel and tumor blood vessel formation, the research seeks to develop therapies that could be effective against both sensitive and resistant forms of ovarian cancer. Patients may benefit from improved detection methods and targeted treatments if the research is successful.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with epithelial ovarian cancer, particularly those at various stages of the disease.
Not a fit: Patients with non-epithelial types of ovarian cancer or those without a diagnosis of ovarian cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier detection and more effective treatments for ovarian cancer.
How similar studies have performed: Previous studies have shown promise in targeting similar proteins for cancer treatment, suggesting that this approach could be viable.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Al-Hilal, Taslim a — University of Utah
- Study coordinator: Al-Hilal, Taslim a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.